Skip to content

Clinical Study on Renal Protective Effect of Yiqi Zishen Huoxue prescription on Patients with Idiopathic Membranous Nephropathy

Clinical Study on Renal Protective Effect of Yiqi Zishen Huoxue prescription on Patients with Idiopathic Membranous Nephropathy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015703
Enrollment
Unknown
Registered
2018-04-16
Start date
2018-04-30
Completion date
Unknown
Last updated
2018-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Membranous Nephropathy

Interventions

Control group:Conventional treatment
test group:Yiqi Zishen Huoxue Recipe+Conventional treatment

Sponsors

Beijing Hospital of Traditional Chinese Medicine affiliated with Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 85 years; 2. Conforms to Western medical diagnostic criteria for idiopathic membranous nephropathy; 3. Consistent with the deficiency of spleen and kidney in Chinese medicine and the diagnostic criteria of blood stasis syndrome; 4. Sign informed consent and are willing to complete the full treatment.

Exclusion criteria

Exclusion criteria: 1. 24-hour urinary protein quantification> 8g/d and serum creatinine> 3mg/dl (265.2umol/L); 2. The use of ACEI/ARB contraindications: renal artery stenosis, hyperkalemia, solitary kidney, etc.; 3. Hormone, immunosuppressant and/or Tripterygium glycoside tablets have been applied in the past 3 months, or hormones, immunosuppressants and/or Tripterygium glycoside tablets are to be applied during the observation period; Acute complications of nephrotic syndrome: infection, severe malnutrition, acute renal failure, thromboembolic diseases; 4. Combining serious primary diseases such as heart, brain, liver or hematopoietic system, malignant tumors, and psychosis; 5. Allergies or allergies to multiple drugs; 6. Pregnancy and lactation women; 7. Request to take other Chinese Herbal Pieces or proprietary Chinese medicines during the observation period.

Design outcomes

Primary

MeasureTime frame
24-hour urine protein quantitation;Albumin;

Secondary

MeasureTime frame
Anti -M phospholipase A2 receptor;Nephrin;podocin;Podocalyxin;Glomerular filtration rate;

Countries

China

Contacts

Public ContactXueyan Sun

Beijing Hospital of Traditional Chinese Medicine affiliated with Capital Medical University

xueyan_sun@163.com+86 15210642151

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026